{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["6-hydroxydopamine", "Dopaminergic neurotransmission", "Modafinil", "Parkinson\u2019s disease", "Rat"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "29071217", "DateRevised": {"Year": "2022", "Month": "03", "Day": "31"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "09", "Day": "25"}], "Language": ["eng"], "ELocationID": ["10.15171/apb.2017.043"], "Journal": {"ISSN": "2228-5881", "JournalIssue": {"Volume": "7", "Issue": "3", "PubDate": {"Year": "2017", "Month": "Sep"}}, "Title": "Advanced pharmaceutical bulletin", "ISOAbbreviation": "Adv Pharm Bull"}, "ArticleTitle": "Modafinil Improves Catalepsy in a Rat 6-Hydroxydopamine Model of Parkinson's Disease; Possible Involvement of Dopaminergic Neurotransmission.", "Pagination": {"StartPage": "359", "EndPage": "365", "MedlinePgn": "359-365"}, "Abstract": {"AbstractText": ["<b><i>Purpose:</i></b> Modafinil is a vigilance-enhancing drug licensed for narcolepsy. The use of modafinil leads to various neuromodulatory effects with very low abuse potential. A body of evidence suggested that modafinil may have anti-parkinsonian effects. This study was designed to evaluate whether modafinil could improve motor dysfunction in the 6-hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease. <b><i>Methods:</i></b> Male Wistar rats (180-220 g, n= 98) were used in this study. Parkinsonism was induced by injection of 6-hydroxydopamine (10 \u03bcg/2\u03bcl in 0.2 % ascorbic acid-saline) into the right striatum. Parkinsonian rats received intraperitoneal (ip) injections of modafinil (50, 75, and 100 mg/kg) and catalepsy-like immobility was assessed by the bar test (BT). Furthermore, involvement of dopamine D<sub>1</sub> and D<sub>2</sub> receptors in modafinil's anti-parkinsonian effects was studied. For this purpose, parkinsonian animals were pretreated with SCH23390 and raclopride (the dopamine D<sub>1</sub> and D<sub>2</sub> receptor anatgonists, respectively) or SCH23390 + raclopride, and then assessed by the BT. <b><i>Results:</i></b> Modafinil (100 mg/kg) showed anti-cataleptic effects in the BT. Notably, the effect of modafinil in the BT was reversed in parkinsonian rats pretreated with raclopride (1.25 mg/kg) and/or SCH23390 + raclopride (0.75 and 1.25 mg/kg, respectively), but not in those pretreated with SCH23390 (0.75 mg/kg). <b><i>Conclusion:</i></b> Acute administration of modafinil improves 6-OHDA-induced motor impairment possibly through activation of dopamine D<sub>2</sub> receptors."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of veterinary, Miyaneh branch, Islamic Azad University, Miyaneh, Iran."}], "LastName": "Vajdi-Hokmabad", "ForeName": "Reza", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plant Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran."}], "LastName": "Ziaee", "ForeName": "Mojtaba", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran."}], "LastName": "Sadigh-Eteghad", "ForeName": "Saeed", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Immunology, Tabriz Branch, Islamic Azad University, Tabriz, Iran."}], "LastName": "Sandoghchian Shotorbani", "ForeName": "Siamak", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran."}], "LastName": "Mahmoudi", "ForeName": "Javad", "Initials": "J"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Iran", "MedlineTA": "Adv Pharm Bull", "NlmUniqueID": "101578021", "ISSNLinking": "2228-5881"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Haddadi R, Mohajjel Nayebi A, Brooshghalan SE. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-ohda hemi-parkinsonian rats. Neurosci Lett. 2013;555:106\u201311. doi: 10.1016/j.neulet.2013.09.022.", "ArticleIdList": ["10.1016/j.neulet.2013.09.022", "24045063"]}, {"Citation": "Nagatsu T, Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;72:113\u201320.", "ArticleIdList": ["17982884"]}, {"Citation": "Shih MC, Hoexter MQ, Andrade LA, Bressan RA. Parkinson's disease and dopamine transporter neuroimaging: A critical review. Sao Paulo Med J. 2006;124(3):168\u201375.", "ArticleIdList": ["17119698"]}, {"Citation": "Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182\u2013217. doi: 10.1124/pr.110.002642.", "ArticleIdList": ["10.1124/pr.110.002642", "21303898"]}, {"Citation": "Paul ML, Graybiel AM, David JC, Robertson HA. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of parkinson's disease. J Neurosci. 1992;12(10):3729\u201342.", "ArticleIdList": ["PMC6575976", "1357113"]}, {"Citation": "Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol. 1996;50(2-3):275\u2013331. doi: 10.1016/s0301-0082(96)00040-8.", "ArticleIdList": ["10.1016/s0301-0082(96)00040-8", "8971983"]}, {"Citation": "Zhao R, Lu W, Fang X, Guo L, Yang Z, Ye N. et al. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease. Pharmacol Biochem Behav. 2014;124:204\u201310. doi: 10.1016/j.pbb.2014.06.011.", "ArticleIdList": ["10.1016/j.pbb.2014.06.011", "24955866"]}, {"Citation": "Ballion B, Frenois F, Zold CL, Chetrit J, Murer MG, Gonon F. D2 receptor stimulation, but not d1, restores striatal equilibrium in a rat model of parkinsonism. Neurobiol Dis. 2009;35(3):376\u201384. doi: 10.1016/j.nbd.2009.05.019.", "ArticleIdList": ["10.1016/j.nbd.2009.05.019", "19501163"]}, {"Citation": "Mahmoudi J, Farhoudi M, Reyhani-Rad S, Sadigh-Eteghad S. Dampening of serotonergic system through 5HT1A receptors is a promising target for treatment of levodopa induced motor problems. Adv Pharm Bull. 2013;3(2):439\u201341. doi: 10.5681/apb.2013.071.", "ArticleIdList": ["10.5681/apb.2013.071", "PMC3848224", "24312874"]}, {"Citation": "Xiao YL, Fu JM, Dong Z, Yang JQ, Zeng FX, Zhu LX. et al. Neuroprotective mechanism of modafinil on Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Pharmacol Sin. 2004;25(3):301\u20135.", "ArticleIdList": ["15000882"]}, {"Citation": "Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol. 2007;568(1-3):112\u201323. doi: 10.1016/j.ejphar.2007.03.044.", "ArticleIdList": ["10.1016/j.ejphar.2007.03.044", "17477916"]}, {"Citation": "Qu WM, Huang ZL, Xu XH, Matsumoto N, Urade Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci. 2008;28(34):8462\u20139. doi: 10.1523/JNEUROSCI.1819-08.2008.", "ArticleIdList": ["10.1523/JNEUROSCI.1819-08.2008", "PMC6671058", "18716204"]}, {"Citation": "Mahmoudi J, Farhoudi M, Talebi M, Sabermarouf B, Sadigh-Eteghad S. Antidepressant-like effect of modafinil in mice: Evidence for the involvement of the dopaminergic neurotransmission. Pharmacol Rep. 2015;67(3):478\u201384. doi: 10.1016/j.pharep.2014.11.005.", "ArticleIdList": ["10.1016/j.pharep.2014.11.005", "25933957"]}, {"Citation": "Van Vlieta SA, Blezer EL, Jongsma MJ, Vanwersch RA, Olivier B, Philippens IH. Exploring the neuroprotective effects of modafinil in a marmoset parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy. Brain Res. 2008;1189:219\u201328. doi: 10.1016/j.brainres.2007.10.059.", "ArticleIdList": ["10.1016/j.brainres.2007.10.059", "18076869"]}, {"Citation": "Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L. et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther. 2006;319(2):561\u20139. doi: 10.1124/jpet.106.106583.", "ArticleIdList": ["10.1124/jpet.106.106583", "16885432"]}, {"Citation": "Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V. et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther. 2009;329(2):738\u201346. doi: 10.1124/jpet.108.146142.", "ArticleIdList": ["10.1124/jpet.108.146142", "PMC2672878", "19197004"]}, {"Citation": "Reyhani-Rad S, Mohajjel Nayebi A, Mahmoudi J, Samini M, Babapour V. Role of 5-Hydroxytryptamine 1A Receptors in 6-Hydroxydopmaine-induced Catalepsy-like Immobilization in Rats: a Therapeutic Approach for Treating Catalepsy of Parkinson's Disease. Iran J Pharm Res. 2012;11(4):1175\u201381.", "ArticleIdList": ["PMC3813151", "24250551"]}, {"Citation": "Hauber W, Neuscheler P, Nagel J, Muller CE. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats. Eur J Neurosci. 2001;14(8):1287\u201393. doi: 10.1046/j.0953-816x.2001.01759.x.", "ArticleIdList": ["10.1046/j.0953-816x.2001.01759.x", "11703457"]}, {"Citation": "Paxinos GW, Charles W. The rat brain in stereotaxic coordinates. 5th ed. Burlington, MA: Elsevier Academic Press; 2005."}, {"Citation": "Mahmoudi J, Mohajjel Nayebi A, Samini M, Reyhani-Rad S, Babapour V. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats. Pharmacol Rep. 2011;63(4):908\u201314. doi: 10.1016/s1734-1140(11)70606-5.", "ArticleIdList": ["10.1016/s1734-1140(11)70606-5", "22001978"]}, {"Citation": "Bazhenova EY, Kulikov AV, Tikhonova MA, Bazovkina DV, Fursenko DV, Popova NK. On the association between lipopolysaccharide induced catalepsy and serotonin metabolism in the brain of mice genetically different in the predisposition to catalepsy. Pharmacol Biochem Behav. 2013;111:71\u20135. doi: 10.1016/j.pbb.2013.08.009.", "ArticleIdList": ["10.1016/j.pbb.2013.08.009", "23994663"]}, {"Citation": "Fink-Jensen A, Schmidt LS, Dencker D, Sch\u00fclein C, Wess J, W\u00f6rtwein G. et al. Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor. Eur J Pharmacol. 2011;656(1-3):39\u201344.", "ArticleIdList": ["PMC3896864", "21269601"]}, {"Citation": "Tostes JG, Medeiros P, Melo-Thomas L. Modulation of haloperidol-induced catalepsy in rats by GABAergic neural substrate in the inferior colliculus. Neuroscience. 2013;255:212\u20138. doi: 10.1016/j.neuroscience.2013.09.064.", "ArticleIdList": ["10.1016/j.neuroscience.2013.09.064", "24125891"]}, {"Citation": "Di Matteo V, Pierucci M, Esposito E, Crescimanno G, Benigno A, Di Giovanni G. Serotonin modulation of the basal ganglia circuitry: Therapeutic implication for parkinson's disease and other motor disorders. Prog Brain Res. 2008;172:423\u201363. doi: 10.1016/s0079-6123(08)00921-7.", "ArticleIdList": ["10.1016/s0079-6123(08)00921-7", "18772045"]}, {"Citation": "Mohajjel Nayebi A, Sheidaei H. Buspirone improves haloperidol-induced parkinson disease in mice through 5-HT(1A) recaptors. Daru. 2010;18(1):41\u20135.", "ArticleIdList": ["PMC3232083", "22615592"]}, {"Citation": "Schober A. Classic toxin-induced animal models of parkinson\u2019s disease: 6-OHDA and MPTP. Cell Tissue Res. 2004;318(1):215\u201324. doi: 10.1007/s00441-004-0938-y.", "ArticleIdList": ["10.1007/s00441-004-0938-y", "15503155"]}, {"Citation": "Nayebi AM, Rad SR, Saberian M, Azimzadeh S, Samini M. Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT(1A) receptors in rats. Pharmacol Rep. 2010;62(2):258\u201364.", "ArticleIdList": ["20508280"]}, {"Citation": "de Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: A microdialysis study in rats. Neuroreport. 2001;12(16):3533\u20137.", "ArticleIdList": ["11733706"]}, {"Citation": "Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol. 1996;306(1-3):33\u20139. doi: 10.1016/0014-2999(96)00182-3.", "ArticleIdList": ["10.1016/0014-2999(96)00182-3", "8813612"]}, {"Citation": "Swanson CJ, Kalivas PW. Regulation of locomotor activity by metabotropic glutamate receptors in the nucleus accumbens and ventral tegmental area. J Pharmacol Exp Ther. 2000;292(1):406\u201314.", "ArticleIdList": ["10604977"]}, {"Citation": "Kalivas PW, Alesdatter JE. Involvement of n-methyl-d-aspartate receptor stimulation in the ventral tegmental area and amygdala in behavioral sensitization to cocaine. J Pharmacol Exp Ther. 1993;267(1):486\u201395.", "ArticleIdList": ["8229779"]}, {"Citation": "Minzenberg MJ, Carter CS. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477\u2013502. doi: 10.1038/sj.npp.1301534.", "ArticleIdList": ["10.1038/sj.npp.1301534", "17712350"]}, {"Citation": "Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: Evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett. 1998;253(2):135\u20138. doi: 10.1016/s0304-3940(98)00629-6.", "ArticleIdList": ["10.1016/s0304-3940(98)00629-6", "9774168"]}, {"Citation": "Augustin SM, Beeler JA, McGehee DS, Zhuang X. Cyclic AMP and afferent activity govern bidirectional synaptic plasticity in striatopallidal neurons. J Neurosci. 2014;34(19):6692\u20139. doi: 10.1523/JNEUROSCI.3906-13.2014.", "ArticleIdList": ["10.1523/JNEUROSCI.3906-13.2014", "PMC4012319", "24806695"]}, {"Citation": "Araki T, Tanji H, Kato H, Itoyama Y. Sequential changes of dopaminergic receptors in the rat brain after 6-hydroxydopamine lesions of the medial forebrain bundle. J Neurol Sci. 1998;160(2):121\u20137. doi: 10.1016/s0022-510x(98)00248-2.", "ArticleIdList": ["10.1016/s0022-510x(98)00248-2", "9849794"]}, {"Citation": "Narang N, Wamsley JK. Time dependent changes in da uptake sites, D1 and D2 receptor binding and mrna after 6-ohda lesions of the medial forebrain bundle in the rat brain. J Chem Neuroanat. 1995;9(1):41\u201353. doi: 10.1016/0891-0618(95)00064-e.", "ArticleIdList": ["10.1016/0891-0618(95)00064-e", "8527037"]}, {"Citation": "Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D. et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine. Neuroscience. 1995;67(3):631\u201347. doi: 10.1016/0306-4522(95)00066-r.", "ArticleIdList": ["10.1016/0306-4522(95)00066-r", "7675192"]}, {"Citation": "Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nat Rev Neurosci. 2001;2(8):577\u201388. doi: 10.1038/35086062.", "ArticleIdList": ["10.1038/35086062", "11484001"]}, {"Citation": "Blunt SB, Jenner P, Marsden CD. Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with L-DOPA and carbidopa. Brain Res. 1992;582(2):299\u2013311. doi: 10.1016/0006-8993(92)90147-2.", "ArticleIdList": ["10.1016/0006-8993(92)90147-2", "1393551"]}, {"Citation": "Hisahara S, Shimohama S. Dopamine receptors and Parkinson's disease. Int J Med Chem. 2011;2011:403039. doi: 10.1155/2011/403039.", "ArticleIdList": ["10.1155/2011/403039", "PMC4411877", "25954517"]}, {"Citation": "Beninger RJ, Mazurski EJ, Hoffman DC. Receptor subtype-specific dopaminergic agents and unconditioned behavior. Pol J Pharmacol Pharm. 1991;43(6):507\u201328.", "ArticleIdList": ["1687945"]}, {"Citation": "Mahmoudi J, Mohajjel Nayebi A, Reyhani-Rad S, Samini M. Fluoxetine improves the effect of levodopa on 6-hydroxy dopamine-induced motor impairments in rats. Adv Pharm Bull. 2012;2(2):149\u201355. doi: 10.5681/apb.2012.023.", "ArticleIdList": ["10.5681/apb.2012.023", "PMC3846000", "24312786"]}, {"Citation": "Lemke MR. Dopamine agonists in the treatment of non-motor symptoms of parkinson's disease: Depression. Eur J Neurol. 2008;15 Suppl 2:9\u201314. doi: 10.1111/j.1468-1331.2008.02213.x.", "ArticleIdList": ["10.1111/j.1468-1331.2008.02213.x", "18702737"]}, {"Citation": "Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson's disease. Mov Disord. 2002;17(4):775\u201381. doi: 10.1002/mds.10167.", "ArticleIdList": ["10.1002/mds.10167", "12210875"]}, {"Citation": "Happe S, Pirker W, Sauter C, Klosch G, Zeitlhofer J. Successful treatment of excessive daytime sleepiness in parkinson's disease with modafinil. J Neurol. 2001;248(7):632\u20134. doi: 10.1007/s004150170148.", "ArticleIdList": ["10.1007/s004150170148", "11518012"]}]}], "History": [{"Year": "2016", "Month": "11", "Day": "21"}, {"Year": "2017", "Month": "7", "Day": "13"}, {"Year": "2017", "Month": "7", "Day": "16"}, {"Year": "2017", "Month": "10", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "10", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "10", "Day": "27", "Hour": "6", "Minute": "1"}, {"Year": "2017", "Month": "9", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["29071217", "PMC5651056", "10.15171/apb.2017.043"]}}]}